Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers
Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)
DOI: 10.1128/aac.00268-26 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Ashlan J Kunz Coyne und 42 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University…. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Anti-Bacterial Agents, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Ceftazidime-avibactam (CAZ-AVI) is a crucial treatment for multidrug-resistant (MDR) gram-negative infections; however, the impact of treatment timing and outcomes in real-world practice remains unclear. This study evaluated CAZ-AVI use across diverse U.S. centers, with emphasis on early initiation. We conducted a retrospective cohort study at 22 U.S. medical centers (2019–2025), including adults with MDR gram-negative infections who received CAZ-AVI ≥ 72 h. The primary outcome was composite clinical success, defined as 30-day survival, absence of microbiological recurrence, and resolution of fever and/or leukocytosis within 72 h of initiation. Early vs late initiation was assessed at 48 h. Classification and regression tree (CART) analysis was used to identify optimal thresholds. Among 613 patients (median age 60 years, 62.5% male, 57.1% admitted to the ICU within 24 h of index culture), the most common infection source was pneumonia (55.5%), and the most frequent pathogens were Pseudomonas aeruginosa (36.1%) and carbapenem-resistant Enterobacterales (34.7%). Composite clinical success occurred in 64.8%. CAZ-AVI initiation within 48 h was not significantly associated with improved outcomes ( P = 0.064). Among patients who did not receive prior active antimicrobial therapy ( n = 429), CART analysis identified a 42 h threshold. Initiation within 42 h was associated with higher clinical success (73.3% vs 63.4%, P = 0.046) and lower 30-day all-cause mortality (10.7% vs 19.1%, P = 0.030). In patients with pneumonia, the same threshold remained discriminatory, with improved clinical success and lower mortality. CAZ-AVI was effective for MDR gram-negative infections in real-world practice. Among patients without prior active therapy, initiation within 42 h was associated with improved outcomes, including in pneumonia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
- University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.
- Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida, USA.
- Memorial Hospital West, Pembroke Pines, Florida, USA.
- Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.
- University of Kentucky HealthCare, Lexington, Kentucky, USA.
ORCID-Profile: Ashlan J Kunz Coyne, Sean Van Helden, Dana Holger, Wesley D Kufel, Joseph Sassine, Christopher A Jankowski, Kimberly C Claeys, Michael J Rybak
Förderung
- AbbVie
Zitieren
APA
Kunz Coyne, A. J., Judd, C., Lucas, K., Al Musawa, M., Van Helden, S., Holger, D., Althubyani, A., Yost, C., VanDorf, S., Mynatt, R., Kufel, W. D., Hayes, J., Deri, C. R., Wrenn, R. H., Slaton, C. N., Morrisette, T., Davis, M., Cabanilla, M. G., Shald, E., …, & Rybak, M. J. (2026). Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.00268-26
Vancouver
Kunz Coyne AJ, Judd C, Lucas K, Al Musawa M, Van Helden S, Holger D, et al. Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.00268-26
BibTeX
@article{KunzCoyne2026,
author = {Kunz Coyne, Ashlan J and Judd, Chloe and Lucas, Kristen and Al Musawa, Mohammed and Van Helden, Sean and Holger, Dana and Althubyani, Ali and Yost, Christine and VanDorf, Sydney and Mynatt, Ryan and Kufel, Wesley D and Hayes, Jillian and Deri, Connor R and Wrenn, Rebekah H and Slaton, Cara N and Morrisette, Taylor and Davis, Melisa and Cabanilla, M Gabriela and Shald, Elizabeth and White, Bryan P and Sassine, Joseph and Truong, James and Rosenberg, Joshua and Andrade, Justin and Cerenzio, John and Medvedeva, Natalia and Ha, David and Eubank, Taryn A and Garey, Kevin W and Biagi, Mark and Todd, Michaela and Kang-Birken, S Lena and Rux, Caleb and Molina, Kyle C and Jankowski, Christopher A and Claeys, Kimberly C and Venugopalan, Veena and Veve, Michael P and Orzol, Carolina and Eshaya, Mirna and Caniff, Kaylee E and Bleick, Callan and Rybak, Michael J},
title = {Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {6},
doi = {10.1128/aac.00268-26}
}
EUVIMED